Trial Profile
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Hydroxychloroquine; Regorafenib
- Indications Colorectal cancer
- Focus Therapeutic Use
- 23 Jun 2022 Primary endpoint (Efficacy based on progression free survival of vorinostat and hydroxychloroquine compared to Regorafenib) has been met, according to Results published in the British Journal of Cancer.
- 23 Jun 2022 Results published in the British Journal of Cancer
- 08 Apr 2020 Status changed from active, no longer recruiting to completed.